纳米技术在神经退行性疾病中有针对性的药物输送方面取得的进展
Diana Rafieezadeh1, Golkamand Sabeti2, Amirreza Khalaji3
1Department of Cellular and Molecular Biology, Razi University Kermanshah, Iran.
American journal of neurodegenerative disease
|May 22, 2025
概括
功能化纳米颗粒为治疗神经退行性疾病提供了一个有前途的解决方案,通过克服血脑屏障 (BBB) 来实现向药物输送. 这种纳米技术提高了阿尔茨海默氏症和帕金森症等疾病的治疗疗效.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 神经科学是一个神经科学.
背景情况:
- 神经退行性疾病 (阿尔茨海默氏症,帕金森症,多发性硬化症) 由于治疗选择有限和大脑障碍存在,造成了重大挑战.
- 血脑屏障 (BBB) 限制治疗剂的通道,阻碍神经系统疾病的有效治疗.
- 现有的治疗方法往往在生物可用性,循环时间和对受影响的大脑区域的向输送方面扎.
研究的目的:
- 探索功能化纳米粒子 (NP) 克服血脑屏障 (BBB) 的潜力.
- 研究NP的应用,以改善神经退行性疾病中的向药物和基因输送.
- 评估纳米载体系统在改善神经疾病治疗结果方面的有效性.
主要方法:
- 利用各种功能化纳米粒子 (脂质体,聚合物微粒,金纳米粒子) 进行药物和基因输送.
- 研究了用于增强BBB透和保护遗传物质的纳米载体系统.
- 探索了非侵入性给药途径,如鼻内输送,以改善患者的坚持.
主要成果:
- 功能化的NP显示出跨越BBB并实现针对性的治疗药物的潜在潜力.
- 纳米载体系统在保护核酸和改善药物的生物可用性和循环方面取得了成功.
- 金纳米颗粒表现出神经保护和抗炎性质,对阿尔茨海默氏症,帕金森症和中风有益.
结论:
- 功能化纳米颗粒是克服BBB和增强神经退行性疾病的向药物递送的有希望的策略.
- 纳米技术为修改基因表达和解决潜在疾病机制提供了潜力.
- 需要进一步的研究和监管进步来优化这些纳米技术的临床应用.
更多相关视频
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.4K
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.5K
相关概念视频
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
Parkinson's Disease: Overview
410
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
410
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Drug Delivery: Parenteral Route
357
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
357
